NCT04999657已完成不适用
A Prospective, Multi-center, Randomized Controlled, Double-blind, Superiority Clinical Trial Evaluating the Safety and Efficacy of a Non-invasive Low-frequency Tibial Nerve Stimulator for the Treatment of Overactive Bladder
Medtecx Co Ltd.7 个研究点 分布在 1 个国家目标入组 109 人开始时间: 2021年8月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 109
- 试验地点
- 7
- 主要终点
- The change of overactive bladder symptom score (OABSS) after 12-week treatment compared with baseline
研究概览
简要总结
To evaluate the efficacy and safety of non-invasive tibial nerve stimulator for the treatment of overactive bladder under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the clinical trial. The primary safety endpoint will be device-related adverse events. The primary effectiveness endpoint will be the improvement value of overactive bladder symptom score (OABSS) after 12-week treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Women and men aged between 18 and 80 years old (including 18 and 80 years old)；
- •Individual with primary OAB, or with OAB symptoms, satisfies one of the following conditions:
- •① Urinary urgency: sudden and strong desire to urinate, and it is difficult to be subjectively suppressed and delayed urination ;
- •② Urge urinary incontinence: accompanied with urinary urgency or immediately after urinary urgency ;
- •③ Urination frequency: adults urination frequency ≥8 times during the daytime，≥2 times at night, and each urine volume <200 ml .
- •Individual meets the diagnostic criteria of OAB: According to the OABSS questionnaire, urgency score ≥2 points, total score ≥3 points, and symptoms duration ≥3 months;
- •Individual newly diagnosed with OAB have not been medicated, or is able to stop taking OAB-related drugs (M receptor block, β3 receptor agonists) for at least 2 weeks prior to enrollment;
- •The subject has autonomy and can go to the toilet independently;
- •Individual is ambulatory and able to use the toilet independently;
- •Individual is capable and willing to participate in the study and provide the written informed consent.
排除标准
- •Woman is pregnant or lactating, or woman of childbearing age who plans to become pregnant during the study period;
- •Individual has Stress Urinary Incontinence (SUI);
- •Individual has obvious urinary obstruction due to various reasons accompanied by residual urine volume> 100 ml;
- •Individual has an implanted pacemaker, embedded cardioverter defibrillator, or other electrical medical devices (including sacral neuromodulation (SNM) devices)
- •Individual has uncured urinary system infection;
- •Individual has urinary calculus resulting in lower urinary tract symptoms;
- •Individual has congenital urinary tract malformations causing uncured lower urinary tract symptoms;
- •Individual has uncured cancers;
- •Individual had undergone lower urinary tract surgery within 3 months;
- •Individual has neurological diseases or injuries accompanied with uncured lower urinary tract symptoms;
- •Individual has skin breakage, malignant tumor or acute purulent inflammation on the surface of the plantar where the electrode pads are to be placed;
- •Individual has participated in other drug clinical trials medical dev within 3 months, or participated in other ice clinical trials within 30 days;
- •Individual is deemed unsuitable for enrollment in the study by investigator.
结局指标
主要结局
The change of overactive bladder symptom score (OABSS) after 12-week treatment compared with baseline
时间窗: 12 weeks
OABSS is evaluated via 3-day voiding diary and urinary voiding events of the previous week at week 0, 4, 8 and 12 after treatment. Evaluate OABSS improvement from baseline after 12 weeks of treatment and compared between the Treatment and the Control groups
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
终止
1 期
Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal IncontinenceFecal IncontinenceNCT01666405Uroplasty, Inc30
Unknown
不适用
Tibial Nerve Stimulation for Faecal IncontinenceFecal IncontinenceNCT00530933London North West Healthcare NHS Trust66
已完成
2 期
Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) SyndromeMultiple SclerosisOveractive BladderNCT02790307University College, London48
招募中
不适用
Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis.Lower Urinary Tract SymptomsMultiple SclerosisNCT04573673University Hospital, Lille68
Unknown
2 期
Percutaneous Tibial Nerve Stimulation in the Treatment of Anterior Resection Syndrome After Rectal Cancer SurgeryRectal CancerLow Anterior Resection SyndromeNCT02177084IRCCS Azienda Ospedaliero-Universitaria di Bologna12